<DOC>
	<DOCNO>NCT00159952</DOCNO>
	<brief_summary>The purpose study determine effect intensive insulin therapy coagulation fibrinolysis patient affect severe sepsis septic shock . As secondary endpoint investigator determine effect intensive insulin therapy organ dysfunction mortality patient .</brief_summary>
	<brief_title>Effect Hyperglycemia PAI-1 Activity Relationship With Outcome Severe Sepsis Septic Shock</brief_title>
	<detailed_description>BACKGROUND The treatment sepsis do three different level : 1 . Etiologic therapy . The eradication infectious agent primary end-point . An appropriate surgical treatment antibiotic therapy key etiologic therapy . 2 . Symptomatic therapy . It traditional approach Intensive Care Unit . It involve correct symptomatic issue lead death patient , buy time necessary action etiologic pathogenic therapy . The key point symptomatic therapy : ) adequate expansion volemia use cardiovascular-acting drug , maintenance adequate cardiocirculatory homeostasis . Recently demonstrate early aggressive haemodynamic therapy direct maintain mixed venous Oxygen Saturation 70 % improved mortality compare standard approach ( 3 ) ; b ) apply mechanical ventilation adequate maintenance respiratory homeostasis . In fact recently show increased survival rate patient treat low tidal volume ventilation strategy compare standard strategy . 3 . Pathogenic therapy . It consist block inflammatory and/or coagulation pathway different level . In last 30 year number report study different approach ( anti-endotoxin antibody , anti-TNF antibody , anti-IL6 antibody , treatment high dos corticosteroid , etc. ) . While approach show efficacy experimental setting give preventively , effect phase 3 clinical trial . This discrepancy may explain consider : 1 ) system consider chaotic , riddance interdependency response ; 2 ) clinical study treatment apply development sepsis , inflammatory coagulation system still largely activate . Three study recently demonstrate benefit survival : 1 . The treatment low-dosage corticosteroid patient non-responders ACH stimulation test ( 5 ) . This substitutive therapy . It important note treatment high dosage corticosteroid block completely inflammatory response effective ( 6 ) . 2 . The treatment recombinant activate Protein C ( 7 ) increase relative survival rate 20 % . Of note activate Protein C molecule three main mechanism action : anticoagulatory , antiinflammatory profibrinolytic . 3 . In recent study post-surgical patient show significant improvement survival patient treat tight glycemic control within 80 110 mg/dL compare glycemia correct reach high level ( &gt; 215 mg/dL ) ( 8 ) .We still lack definitive explanation finding , discussion mainly relative role glycemia per se versus insulin therapy per se . However , look overall scenario , issue note : 1 . We know complete block inflammatory reaction complete block coagulation cascade improve outcome septic patient 2 . The activated Protein C molecule high spectrum action , particular molecule within numerous molecule test pro-fibrinolytic activity 3 . We know high glycemia per se greatly increase PAI production ( molecule inhibits fibrinolysis ) . 4 . The septic patient primarily die multiple organ dysfunction part due widespread microthrombosis . A possible unifying hypothesis improve outcome observed activate Protein C tight glycemic control due maintenance physiologic fibrinolysis . This hypothesis never test prove could open interest therapeutical approach septic patient expose high mortality risk . OBJECTIVES : The primary end-point evaluation activation/deactivation fibrinolytic system two-randomization group . STUDY DESIGN : This study multicenter , randomize , Phase 2/3 study adult patient severe sepsis septic shock . We enroll total approximately 80 adult patient . TREATMENTS ADMINISTERED 1 . Control : glycemia control insulin administration high 215 mg/dL . 2 . Treatment : glycemia control controlled insulin administration high 110 mg/dL . RANDOMIZATION : The patient enrol undergo block-randomization center two arm stratify accord clinical decision care physician use use activate Protein C. DATA COLLECTION : The clinical variable biochemical variable fibrinolysis , coagulation , contact phase pro-inflammatory cytokine record daily first 7 day , second day 14 day fifth end study ( 28th day , dimission/death ) . At Baseline : Demographic data Every 24 hour : 1 . Simplified Acute Physiology Score II ( SAPS II ) ( 9 ) . The Simplified Acute Physiology Score assess severity illness basis 12 physiological variable ; age , type admission ( urgent nonurgent ) 3 variable relate underlying disease . Scores range 0 194 ; high score correlate high risk death hospitalization 2 . SOFA ( Sepsis-related Organ Failure Assessment ) ( 10 ) . It index multi-organ dysfunction ( range 0-24 ) . 3 . Ramsey scale ( 11 ) . It index level sedation ( range 1-6 ) . 4 . Respiratory , circulatory biochemical variable monitor organ dysfunction ( 4 ) . The main biochemical variable collect : - Fibrinolytic system : 1 . PAI-1 activity 2 . PAI- 1 antigen 3. tPA antigen 4 . Plasmin-antiplasmin complex ( PAP ) 5 . D-Dimer fragment 6 . Polymorphism 4G/5 PAI-1 gene - Final phase pf coagulation pathway 1 . Thrombin-antithrombin complex ( TAT ) 2 . Prothrombin fragment F1 + 2 - Contact system 1 . Activated Factor XII ( FXIIa ) 2 . Metabolism endogenous bradykinin 3 . Polymorphism insertion/deletion gene angiotensin convert enzyme - Inflammation 1 . C reactive protein ( CRP ) 2 . Interleukin-6 ( IL-6 ) 3 . Tumor necrosis factor ( TNF ) 4 . C3a 5 . SC5b-9 SAFETY ASPECTS AND SEVERE ADVERSE EVENTS ( SAE ) REPORTING : GCP rule strictly apply , include timely report study coordination within 48 hour occurrence SAEs include efficacy end-points . Clinical investigator nurse participate center instruct monitor specifically document adverse event likely associate study treatment . STATISTICAL ASPECTS : plan enroll 80 septic patient ICU relate participate research unit . This size allow show average difference 30 % fibrinolysis biochemical parameter ( alfa = 0.05 , 1-beta = 0.80 ) . ADMINISTRATIVE , LEGAL , ETHICAL ISSUES : This study design collaborative group , active last ten year conduct clinical trial intensive care . The study plan manage independently , clinician take active part study receive economic incentive . The Ely Lilly Italia Spa provide financial support perform laboratory test require study fibrinolysis . It important emphasize comparing effect two different strategy glycemic control fibrinolysis . The Ely Lilly interest study scientific , , could show importance fibrinolysis sepsis , could elucidate one putative mechanism activate Protein C action . This study also partially fund grant Ministry University research ( COFIN 2004 ) . The data produce belong study group , ensure publication availability public authority . All data relate patient include study treat strict compliance Italian Laws relate privacy 675/1996 . The informed consent patient administer soon every time clinical condition patient compatible procedure , thus follow provision set forth ICH-GCP guideline ( 13 ) , confirm recent European Directive 2001/20/CE Decreto Legislativo 211 24/06/2003 . It worth recall legal basis require consent relative patient . REFERENCES 1 . Gattinoni L , Vagginelli F , Taccone P , Carlesso E , Bertoja E , Sepsis : state art . Minerva Anestesiologica 2003 ; 69 : 17-28 . 2 . Salvo I , de Cian W , Musico M. Langer M , Piadina R , Wolfer A , et al . The Italian SEPSIS study : preliminary result incidence evolution SIRS , sepsis , severe sepsis septic shock . Intensive Care Medicine 1995 ; 21 Suppl . 2 : S244-249 . 3 . Rivers E , Nguyen B , Havstad S , Ressler J , Muzzin A , Knoblich B , et al . Early goal-directed therapy treatment severe sepsis septic shock . The New England Journal Medicine 2001 ; 345 : 1368-1377 4 . Ventilation low tidal volume compare traditional tidal volume acute lung injury acute respiratory distress syndrome . The New England Journal Medicine 2000 ; 342 : 1301-1308 5 . Annane D , Sibille V , Charpentier C , Bollaert PE , Francois B , Korach JM , et al . Effect treatment low dose hydrocortisone fludrocortisone mortality patient septic shock . JAMA 2002 ; 288 : 862-871 6 . Bone RC , Fischer CJJ , Clemer TP , Slotman GJ , Metz CA Balk RA . A control clinical trial high-dose methyl-prednisolone treatment severe sepsis septic shock . The New England Journal Medicine 1987 ; 317 : 653-658 7 . Bernard GR , Vincent JL , Laterre PF , La Rosa SP , Dhainaut JF , Lopez-Rodriguez A , et al . Efficacy safety recombinant human activate protein C severe sepsis . The New England Journal Medicine 2001 ; 344:699-709 8 . Van de Berghe G , Wouters P , Weekers F , Verwaest C , Brunynckx F , Schets M , et al . Intensive insulin therapy critically ill patient . New Engl j med 2001 ; 345:1359-1367 9 . Knaus WA , Draper EA , Wagner DP , Zimmerman JE , APACHE II : severity disease classification system . Crit Care Med 1985 ; 13 : 818-829 10 . Vincent JL , de Mendonca A , Contraine F , Moreno R , Takala J , Suter PM , Sprung CL , Colardyn F , Blecher S , Use SOFA score ass incidence organ dysfunction/failure intensive care unit : result multicenter prospective study . Working group `` sepsis-related problem '' European Society Intensive Care Medicine . Crit Care Med 1998 ; 26:1793-800 11 . Ramsay MAE , Savege TM , Simpson BRJ et al . : Controlled sedation alphaxalone-alphadolone . Br Med J 1974 ; 2 : 656-659 12 . Dhainaut JF , Yan SB , Cariou A , Mira JP . Soluble thrombomodulin , plasma-derived unactivated protein C , recombinant human activate protein C sepsis . Crit Care Med 2002 May ; 30 ( 5 Suppl ) : S318-24 13 . Guidelines Good Clinical Practice , par . 4.8 . ICH Steering Committee meeting . 1 May 1996 .</detailed_description>
	<mesh_term>Shock</mesh_term>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Shock , Septic</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Patients sepsis , severe sepsis sepsis shock define follow : Sepsis : Systemic response infection two follow condition : Body temperature &lt; 36° &gt; 38° Heart rate &gt; 90 bpm Respiratory rate &gt; 20 bpm PaCO2 &lt; 32 torr White cell count &gt; 12000 mm3 &lt; 4000 mm3 differential count show &gt; 10 % immature neutrophile Severe sepsis : Sepsis associate organ dysfunction . Sepsis shock : Sepsis associate hypotension despite adequate fluid resuscitation , hypoperfusion include lactic acidosis , oliguria acute alteration consciousness . The hypotension need present patient treat inotropic vasoactive drug . Age 16 year Patients hematologic malignancy bone marrow transplant Patients type I diabetes Patients expect early death underlie disease .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Sepsis</keyword>
	<keyword>Septic shock</keyword>
	<keyword>Hyperglycemia</keyword>
	<keyword>Fibrinolysis</keyword>
	<keyword>PAI 1</keyword>
</DOC>